Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desloratadine 5 mg for intermittent allergic rhinitis
2005-005449-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing Desloratadine 5 mg with Placebo (2 arms). Primary endpoint: Change from baseline in 12-hour AM/PM prior reflective total 5 symptom score. Started May 2006; status: completed.
02
Drugs
desloratadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2005-005449-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005449-20.